McDermott and Bull executive Search
 

Other News

OneProjects Announces $17 Million in New Financing to Advance Development of 4D Cardiac Imaging Technology

DUBLIN & MUNICH–(BUSINESS WIRE)–OneProjects, developer of four-dimensional (4D) cardiac imaging technology, today announced a total of $17 million in new financing for the company, including an $8 million Series A2 financing and two grants worth $9 million. The Series A2 financing was led by imec.xpand, with participation from the European […]

First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., Oct. 14, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support […]

Abcentra Appoints Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

LOS ANGELES, Oct. 14, 2021 /PRNewswire/ — Abcentra LLC announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors. Dr. Davidson is currently CEO of New Amsterdam Pharma, and was previously the founding CEO and Chief Medical Officer of Corvidia Therapeutics, which was acquired by Novo-Nordisk in 2020. He also co-founded […]

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

Trial to evaluate new technology that may help physicians prevent heart attacks in patients REDWOOD CITY, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque […]

PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx’s VAZALORE Specifically Indicated for Secondary Prevention

Aspirin remains an established practice for the prevention of another heart attack or clot-related stroke SPARTA, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective […]

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

The U.S. STAR-D and already recruiting STAR-T randomized controlled pivotal trials are intended to establish DrugSorb-ATR as a single, easy-to-use solution for the reduction of perioperative bleeding in open heart surgery patients caused by the most widely prescribed next generation antiplatelet and anticoagulant drugs MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ — CytoSorbents […]

CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminary core non-COVID-19 product sales increased 4% Y-Y to approximately $7.8 million. MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood […]

Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate Zynex

ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q3 2021. Thomas Sandgaard, CEO of Zynex said: “Our order […]

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from […]